Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,940,875
  • Shares Outstanding, K 37,515
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,140 K
  • EBIT $ -68 M
  • EBITDA $ -67 M
  • 60-Month Beta -1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 3
  • High Estimate -0.50
  • Low Estimate -0.55
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -65.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.99 +12.32%
on 12/12/25
170.24 -6.98%
on 01/08/26
+9.23 (+6.19%)
since 12/09/25
3-Month
77.64 +103.97%
on 10/10/25
170.24 -6.98%
on 01/08/26
+79.86 (+101.73%)
since 10/09/25
52-Week
49.00 +223.18%
on 04/09/25
170.24 -6.98%
on 01/08/26
+102.42 (+183.09%)
since 01/08/25

Most Recent Stories

More News
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 158.36 (-3.44%)
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 158.36 (-3.44%)
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033 Tinlarebant met...

BLTE : 158.36 (-3.44%)
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential...

BLTE : 158.36 (-3.44%)
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

BLTE : 158.36 (-3.44%)
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

MHRA response is based on the Phase 3 DRAGON interim analysis results  Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE),...

BLTE : 158.36 (-3.44%)
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

BLTE : 158.36 (-3.44%)
H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $98.00. The company’s shares closed yesterday at $81.26.Elevate Your Investing...

BLTE : 158.36 (-3.44%)
Leerink Partners Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)

Leerink Partners analyst Marc Goodman reiterated a Buy rating on Belite Bio, Inc. ADR today. The company’s shares opened today at $80.00.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

BLTE : 158.36 (-3.44%)
Belite Bio to Participate in the 2025 Maxim Growth Summit

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

BLTE : 158.36 (-3.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 174.92
2nd Resistance Point 170.46
1st Resistance Point 164.41
Last Price 158.36
1st Support Level 153.90
2nd Support Level 149.44
3rd Support Level 143.39

See More

52-Week High 170.24
Last Price 158.36
Fibonacci 61.8% 123.93
Fibonacci 50% 109.62
Fibonacci 38.2% 95.32
52-Week Low 49.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar